: AstraZeneca, London’s biggest listed company, is looking at plans to spin off its Chinese businesses to protect it from geopolitical tension, reported German news agency .
By separating off its Chinese arm, the drugs giant hopes to be better protected against political reprisals from Beijing against foreign companies. Along with the US, Japan, Germany and France, China is one of the world’s top five biggest pharmaceutical markets. But in last year’s annual report, the company warned that “over the next two decades, the geopolitical environment is expected to become more contested, potentially reaching levels of intensity not seen since the Cold War”.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: